Date/Time: October 5–8, 2025 Location: Prague Congress Centre, Prague, Czech Republic Official Congress Website: https：//wcp-comgress.com/ YINGCHI Booth: #13 Join YINGCHI at the World Congress of Psychiatry This October, YINGCHI will participate in the 25th World Congress of Psychiatry (WCP 2025), organized by the World Psychiatric Association (WPA) in Prague, Czech Republic. With the theme “The Role... Read more
The first onset of major depressive disorder (MDD) during adolescence is often associated with a lifelong risk of recurrence and functional impairment, making early and effective intervention crucial for adolescent patients with depression. However, pharmacological treatments are slow-acting and may have side effects, while psychotherapy is time-consuming and unable to rapidly alleviate symptoms. Therefore, developing... Read more
On June 10, a team from Fudan University, Department of Neurology at Fudan University Affiliated Pudong Hospital, published new research in Neurotherapeutics (2025 Impact Factor: 6.9): Enhancing working memory in MCI: Modulating alpha-gamma coupling and gamma oscillations via rTMS. Background Introduction Working memory (WM) is a core cognitive function essential for everyday behavior and complex mental processing.... Read more
In 2025, great news arrives! Shenzhen Hanix United, Ltd. (hereinafter referred to as "Hanix") and the global leader in EEG technology, Brain Products GmbH (hereinafter referred to as "BP"), celebrate the glorious 20th anniversary of their strategic partnership! Twenty Years of Collaboration From the First ERP Workshop to a Nationwide Research Network In 2005, Hanix... Read more
Date/Time: June 12-14, 2025 Location: San DiegoSheraton San Diego Hotel & Marina1380 Harbor Island Dr, San Diego, CA 92101 YINGCHI Booth: #305 Detail Information YINGCHI is pleased to announce its participation in the 13th Annual Meeting of the Clinical TMS Society (#CTMSS2025), to be held from June 12 to 14, 2025, at the Sheraton San... Read more
We are thrilled to announce that YINGCHI TMS has received new FDA granted clearances for two major treatment indications: ? YINGCHI rTMS for Obsessive-Compulsive Disorder (OCD) – K243459 ? Intermittent Theta Burst Stimulation (iTBS) for Major Depressive Disorder – K243460 So far, YINGCHI TMS has been approved by FDA for rTMS treating OCD, rTMS treating MDD,... Read more
